Monoclonal antibodies are created using hybridoma technology. This involves injecting a mouse with an antigen that provokes an immune response, extracting the spleen cells that produce antibodies, and then fusing these cells with myeloma cells. The resulting hybrid cells, or hybridomas, are capable of both producing antibodies and dividing indefinitely. The antibodies they produce are then harvested and purified for use in cancer treatment.
